US 12,263,180 B2
Method for treatment of COVID-19-associated conditions
Esteban Masuda, Menlo Park, CA (US); and Vadim Markovtsov, San Mateo, CA (US)
Assigned to Rigel Pharmaceuticals, Inc., South San Francisco, CA (US)
Filed by Rigel Pharmaceuticals, Inc., South San Francisco, CA (US)
Filed on May 18, 2021, as Appl. No. 17/323,901.
Application 17/323,901 is a continuation of application No. PCT/US2021/021951, filed on Mar. 11, 2021.
Claims priority of provisional application 62/988,876, filed on Mar. 12, 2020.
Claims priority of provisional application 63/038,570, filed on Jun. 12, 2020.
Prior Publication US 2021/0283152 A1, Sep. 16, 2021
Int. Cl. A61K 31/5383 (2006.01); A61K 31/155 (2006.01); A61K 31/245 (2006.01); A61K 31/427 (2006.01); A61K 31/4706 (2006.01); A61K 31/4748 (2006.01); A61K 31/519 (2006.01); A61K 31/573 (2006.01); A61K 31/675 (2006.01); A61K 31/7048 (2006.01); A61K 39/42 (2006.01); A61P 31/14 (2006.01); C07K 16/10 (2006.01)
CPC A61K 31/675 (2013.01) [A61K 31/155 (2013.01); A61K 31/245 (2013.01); A61K 31/427 (2013.01); A61K 31/4706 (2013.01); A61K 31/4748 (2013.01); A61K 31/519 (2013.01); A61K 31/573 (2013.01); A61K 31/7048 (2013.01); A61K 39/42 (2013.01); A61P 31/14 (2018.01); C07K 16/1003 (2023.08)] 39 Claims
 
1. A method of treatment of a COVID-19 infection, comprising:
administering to a patient having or suspected of having the COVID-19 infection, a compound, wherein the compound is of the formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, or

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.